ASH24: Matthew Davids, MD, MMSC | Dana-Farber Cancer Institute

In a new study published in the Journal of Clinical Oncology and presented at #ASH24, Matthew Davids, MD, MMSC, of Dana-Farber Cancer Institute, shared promising findings: a time-limited AVO triplet therapy offers durable remission for high-risk CLL patients.
Read more: bit.ly/3D3OCPP
Video published 12/18/2024